Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer

Novel chemo-immunotherapy (chemo-IO) combinations should be evaluated, which may be suitable for cisplatin-unfit or fluoropyrimide-ineligible patients with recurrent or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) to guarantee higher and deeper responses than IO alone. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabezas-Camarero, Santiago, Merino-Menéndez, Salomé, Cabrera-Martín, María Nieves, Sotelo, Miguel J., Plaza-Hernández, José Carlos, Falahat, Farzin, Iglesias-Moreno, María Cruz, Pérez-Segura, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773311/
https://www.ncbi.nlm.nih.gov/pubmed/36589672
http://dx.doi.org/10.3892/ol.2022.13623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773311/
https://www.ncbi.nlm.nih.gov/pubmed/36589672
http://dx.doi.org/10.3892/ol.2022.13623

Ejemplares similares